(Q34241224)

31 July 2017

1 reference

title

Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis (English)

1 reference

31 July 2017

0 references

1 reference

1 reference

S R Money

1

1 reference

PubMed ID

11336843

31 July 2017

J W York

series ordinal

2

1 reference

31 July 2017

1 June 2001

1 reference

31 July 2017

1 reference

31 July 2017

9

1 reference

31 July 2017

211-218

1 reference

31 July 2017

3

1 reference

https://api.crossref.org/works/10.1016%2FS0967-2109%2800%2900144-7

31 July 2017

1 reference

7 January 2021

A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0967-2109%2800%2900144-7

7 January 2021

Acute pulmonary thromboembolism: has its evolution been redefined?

1 reference

https://api.crossref.org/works/10.1016%2FS0967-2109%2800%2900144-7

7 January 2021

History of drugs for thrombotic disease. Discovery, development, and directions for the future

1 reference

https://api.crossref.org/works/10.1016%2FS0967-2109%2800%2900144-7

7 January 2021

Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0967-2109%2800%2900144-7

7 January 2021

Pharmacology of heparin and warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0967-2109%2800%2900144-7

7 January 2021

Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: pharmacological considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0967-2109%2800%2900144-7

7 January 2021

Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0967-2109%2800%2900144-7

7 January 2021

Oral low-molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0967-2109%2800%2900144-7

7 January 2021

Orally administered heparin for preventing deep venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0967-2109%2800%2900144-7

7 January 2021

An assay for the antithrombotic activity of anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS0967-2109%2800%2900144-7

7 January 2021

Induced thrombosis in the pig inferior vena cava: a model of deep venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0967-2109%2800%2900144-7

7 January 2021

Treatment of experimentally induced caval thrombosis with oral low molecular weight heparin and delivery agent in a porcine model of deep venous thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0967-2109%2800%2900144-7

7 January 2021

Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0967-2109%2800%2900144-7

7 January 2021

10.1016/S0967-2109(00)00144-7

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11336843